Breaking News
Get 40% Off 0
🔮 Better than the Oracle? Our Fair Value found this +42% bagger 5 months before Buffett bought it Read More
Close

Sarepta Therapeutics Inc (SRPT)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Sarepta's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
125.00 +5.02    +4.18%
15:59:59 - Closed. Currency in USD ( Disclaimer )
After Hours
123.00
-2.00
-1.60%
19:56:33 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 2,161,584
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 122.22 - 125.84
Sarepta 125.00 +5.02 +4.18%

Sarepta Therapeutics Inc Company Profile

 
Get an in-depth profile of Sarepta Therapeutics Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

1162

Equity Type

ORD

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children’s Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Contact Information

Address 215 First Street Suite 415
Cambridge, 02142
United States
Phone 617 274 4000
Fax -

Top Executives

Name Age Since Title
Douglas S. Ingram 58 2017 President, CEO & Director
M. Kathleen Behrens 69 2009 Independent Chairwoman
Beverly L. Davidson - 2015 Member of Strategic & Scientific Advisory Board
Hans Wigzell 83 2010 Chairman of Corporate Strategy Board & Independent Non-Employee Director
Louis M. Kunkel - 2015 Member of Strategic & Scientific Advisory Board
Kenneth H. Fischbeck - 2017 Member of Strategic & Scientific Advisory Board
Matthew Wood - 2017 Member of Strategic & Scientific Advisory Board
Steven Gray - 2019 Member of Scientific Advisory Board
Angela J. Russell - 2020 Member of Scientific Advisory Board
Carsten Bonnemann - 2019 Member of Scientific Advisory Board
Kay Davies - 2019 Member of Scientific Advisory Board
Annemieke Aartsma-Rus - 2019 Member of Scientific Advisory Board
Joy A. Cavagnaro - 2019 Member of Scientific Advisory Board
Stephen L. Mayo 60 2021 Independent Director
Michael Chambers 48 2022 Independent Director
Kathryn J. Boor 64 2022 Independent Director
Claude Nicaise 70 2015 Independent Non-Employee Director
Richard Jon Barry 64 2015 Independent Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

SRPT Comments

Write your thoughts about Sarepta Therapeutics Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Sean Weatherly
Sean Weatherly Dec 15, 2023 9:28AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Archer Aviation 🥳
Nov 02, 2023 7:18AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Are we going back to 100$?
Shawn Aslani
Shawn Aslani Jun 23, 2023 10:21AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
90 $ very soon
AKIN SARI
SCAR Sep 30, 2021 3:28PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
120+ very soon
Ray Ray
Ray Ray Apr 07, 2021 1:09PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Huge Discount BUY BUY BUY!!!
Eduardo Menezes
Eduardo Menezes Apr 07, 2021 1:09PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Good timing
Ray Ray
Ray Ray Apr 01, 2021 5:00AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Target is 82$
Ray Ray
Ray Ray Mar 30, 2021 5:04AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
this company is trash
Daniel Gazey
DJG93 Mar 30, 2021 5:04AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
On the 19th you said it will hit 100s, make up your mind
Ray Ray
Ray Ray Mar 30, 2021 5:04AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
it will but looks like it will take 3 months. But I added 100 lots more.
Daniel Gazey
DJG93 Mar 30, 2021 5:04AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I was hopeful it would bounce from the over reaction, bought at $91 after the dip...playing the long game now, but painful right now
Captain Capitalist
Captain Capitalist Mar 19, 2021 11:18AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Going big.
Ray Ray
Ray Ray Mar 19, 2021 10:12AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
market is ********up right now. just wait couple months and it will hit 100s
Ryan Turla
Ryan Turla Mar 19, 2021 8:35AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Sell on the news
Maa Paa
GiGi__GiGi Mar 19, 2021 8:35AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
link?
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email